HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamide

an aurora kinase inhibitor and antineoplastic agent; structure in first source
Also Known As:
PF 03814735; PF-03814735; PF03814735
Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Christensen, James G: 2 articles (03/2012 - 04/2010)
2. Yuan, Jing: 1 article (03/2012)
3. Lee, Nathan V: 1 article (03/2012)
4. Pavlicek, Adam: 1 article (03/2012)
5. Kan, Julie L C: 1 article (03/2012)
6. Ye, Jingjing: 1 article (03/2012)
7. Shi, Stephanie T: 1 article (03/2012)
8. Rejto, Paul A: 1 article (03/2012)
9. Ching, Keith A: 1 article (03/2012)
10. Zheng, Xianxian: 1 article (03/2012)

Related Diseases

1. Retinoblastoma (Glioblastoma, Retinal)
2. Neoplasms (Cancer)
3. Small Cell Lung Carcinoma (Small Cell Lung Cancer)
4. Polyploidy
5. Colonic Neoplasms (Colon Cancer)

Related Drugs and Biologics

1. aurora kinase (aurora A kinase)
2. MART-1 Antigen
3. Interleukin 1 Receptor Antagonist Protein (Anakinra)
4. Sirolimus (Rapamycin)
5. Simvastatin (Zocor)
6. Daptomycin
7. Paclitaxel (Taxol)
8. Endothelins (Endothelin)
9. Fibrin Tissue Adhesive (Fibrin Sealant)
10. Biological Markers (Surrogate Marker)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Stents
3. Oral Administration